Vertex Pharmaceuticals Incorporated (VIE:VRTX)

Austria flag Austria · Delayed Price · Currency is EUR
392.20
-2.90 (-0.73%)
At close: Dec 5, 2025
-10.43%
Market Cap 99.34B
Revenue (ttm) 9.99B
Net Income (ttm) 3.13B
Shares Out n/a
EPS (ttm) 12.12
PE Ratio 31.71
Forward PE 22.33
Dividend n/a
Ex-Dividend Date n/a
Volume 31
Average Volume 22
Open 393.55
Previous Close 395.10
Day's Range 392.20 - 393.55
52-Week Range 313.80 - 474.60
Beta n/a
RSI 66.38
Earnings Date Feb 2, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1989
Employees 6,100
Stock Exchange Vienna Stock Exchange
Ticker Symbol VRTX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.